Specialized Program Of Research Excellence (SPORE) in Leukemia

白血病专业卓越研究计划 (SPORE)

• 批准号: 9307740
• 负责人: Daniel C Link
• 金额: $ 230万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-03 至 2018-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9307740
• 关键词: Acute Lymphocytic Leukemia; Acute Myelocytic Leukemia; Agreement; Attenuated; Basic Science; Biological Assay; Biometry; Blast Cell; Bone Marrow; CSF3 gene; CXCR4 gene; Cells; Clinical; Collaborations; DNA Methylation; Decitabine; Development; Disabled Persons; Dysmyelopoietic Syndromes; Epigenetic Process; Female; Gene Expression Profile; Gene Mutation; Genome; Genomics; Goals; Hematopoiesis; Immunology; Institution; Iowa; Lymphoma; Lymphopoiesis; Marrow; Mentors; Methods; Minority; Molecular; Mutation; Ohio; Patients; Program Development; RNA Splicing; Recruitment Activity; Regulatory T-Lymphocyte; Research; Research Infrastructure; Research Personnel; Resources; Specialized Program of Research Excellence; Spliced Genes; Stem cells; Syndrome; Technology; Testing; Training; Translational Research; Universities; Washington; cancer genome; cancer genomics; career development; chemotherapy; graft vs host disease; innovation; leukemia; leukemia treatment; next generation sequencing; novel; novel marker; novel strategies; predicting response; programs; public health relevance; response; translational cancer research

DESCRIPTION (provided by applicant): The Washington University SPORE in Leukemia is a highly dynamic translational cancer research program that focuses specifically on leukemias and myelodysplastic syndromes (MDS). We have assembled an outstanding group of investigators with complementary expertise in basic and clinical leukemia research. In this SPORE, we leverage expertise in cancer genomics, immunology, and hematopoiesis to develop innovative translational research in leukemia. Our long term goal is to develop novel biomarkers and treatments for leukemias and MDS and to recruit and promote innovative translational leukemia research. To achieve these goals, the following specific aims are proposed. Aim 1. To exploit recent advances in cancer genomics to develop novel biomarkers and treatments for leukemias and MDS. Washington University has been at the forefront of genomic studies in AML and MDS. Through sequencing of primary acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) genomes, we identified several novel recurring mutations of genes involved in DNA methylation (DNMT3A and IDH1) and RNA splicing (U2AF1). This basic research has led to the development of the following two translational SPORE projects. Project 1. Molecular determinants of decitabine responsiveness Project 3. Development of RNA splicing modulators for myelodysplastic syndromes and AML. Aim 2. To leverage local expertise in immunology and hematopoiesis to develop novel treatments for leukemias and myelodvsplastic syndromes. Institutional expertise in basic immunology and hematopoiesis research has led to the development of two innovative translational projects in leukemia. Project 2. Targeting the bone marrow microenvironment in acute lymphocytic leukemia. Project 4. Epigenetic modulation of graft versus host disease and graft versus leukemia. Aim 3. To enhance the infrastructure that supports translational leukemia research. This SPORE will support the following Shared Research Resources: 1) Core A. Biospecimen Processing; 2) Core B. Biostatistics; and 3) Core C. Administration. Aim 4. To recruit and train new investigators in translational research. Aim 5. To facilitate inter-SPORE collaboration.

描述（由申请人提供）：华盛顿大学白血病SPORE是一个高度动态的转化性癌症研究项目，专门关注白血病和骨髓增生异常综合征（MDS）。我们汇集了一群优秀的研究人员，他们在基础和临床白血病研究方面具有互补的专业知识。在这个孢子中，我们利用癌症基因组学，免疫学和造血方面的专业知识来开发白血病的创新转化研究。我们的长期目标是开发白血病和MDS的新型生物标志物和治疗方法，并招募和促进创新的转化性白血病研究。为了实现这些目标，提出了以下具体目标。